Chasing mutations in the epidermal growth factor in lung cancer

New England Journal of Medicine

Volumn 352, Issue 8, 2005, Pages 830-832

  Dowell, Jonathan E ^a,b   Minna, John D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; ANILINOQUINAZOLINE; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; ISOLEUCINE; METHIONINE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; STEM CELL FACTOR; THREONINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ALLELE; AMINO ACID SUBSTITUTION; APOPTOSIS; BCR ABL GENE; BINDING SITE; BIOLOGICAL MODEL; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COMPUTER MODEL; DRUG APPROVAL; DRUG TARGETING; EDITORIAL; EGFR GENE; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENOME; GENOME WIDE SEARCH; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR MODEL; MULTIDRUG RESISTANCE; ONCOGENE; ONCOGENE C KIT; ONCOGENE NEU; PHOSPHATIDYLINOSITOL 3 KINASE GENE; POINT MUTATION; PRECANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR BIOPSY; TYROSINE KINASE DOMAIN; UNITED STATES; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; LUNG TUMOR; MUTATION; NOTE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENES, ABL; HUMANS; LUNG NEOPLASMS; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 13844321724     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058033     Document Type: Editorial

References (6)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Weinstein IB. Cancer: addiction to oncogenes - the Achilles heal of cancer. Science 2002;297:63-4.
4. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
5. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
6. Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435-40.